South Korea’s Genome & Co. Ltd. (KOSDAQ:314130) shares rose nearly 30% June 3 after it disclosed a potential ₩586.38 billion (US$426 million) licensing deal for its novel antibody-drug conjugate candidate with Switzerland’s Debiopharm International SA.
While there was much talk about the vast potential of artificial intelligence (AI) during one of the world’s largest research cancer conferences, antibody-drug conjugates (ADCs) continued to grab the lion’s share of attention as Corbus Pharmaceuticals Holdings Inc. and Takeda Pharmaceutical Co. Ltd. released new and positive data.
Almac Discovery Ltd. has nominated a new preclinical candidate molecule, ALM-401, a first-in-class bispecific antibody-drug conjugate (ADC) targeting EGFR/ROR1. It is being developed for the treatment of refractory lung cancer characterized by dual expression of ROR1 and EGFR.
China’s Medilink Therapeutics (Suzhou) Co. Ltd. and Germany’s Biontech SE signed another potential $1 billion-plus deal for novel antibody-drug conjugate (ADC) targets, building off the first ADC-based licensing deal from last year.
A group of scientists from Basel University Hospital have designed an antibody-drug conjugate (ADC) that eliminated blood cancer cells without attacking healthy hematopoietic stem cells (HSCs), which they modified by base editing and transplanted to renew an altered blood system. They achieved this by focusing on the panhematopoietic marker CD45.
Cambridge, U.K.-based Astrazeneca plc is looking to Asia, specifically China and Singapore, to build an innovative cancer-focused pipeline filled with antibody-drug conjugates (ADC), monoclonal antibodies (MAbs) and cell therapies.
Cambridge, U.K.-based Astrazeneca plc is looking to Asia, specifically China and Singapore, to build an innovative cancer-focused pipeline filled with antibody-drug conjugates (ADC), monoclonal antibodies (MAbs) and cell therapies.
Pheon Therapeutics Ltd. is poised to start the first of three clinical trials of its lead antibody-drug conjugate (ADC), after closing a $120 million series B. The company is taking a “three-pronged approach” in order to stake out as much of the ground as it can for its next-generation ADC, which delivers an in-house-designed topoisomerase inhibitor to a novel undisclosed transmembrane protein target.
Pheon Therapeutics Ltd. has completed a $120 million series B financing to fund the development of its pipeline of differentiated antibody-drug conjugates (ADCs) for cancer through clinical proof of concept.
Even though HER3 is validated as a promising therapeutic target for cancer therapy, no HER3-targeting antibodies or antibody-drug conjugates (ADCs) have been approved for clinical use. Investigators at Duality Biologics (Suzhou) Co. Ltd. have developed DB-1310, a new HER3-targeting ADC being studied for the treatment of solid tumors, and published findings from preclinical characterization.
RSS
